Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Tarsus Pharmaceuticals In...

    NASDAQ: TARS · Real-Time Price · USD
    41.37
    0.77 (1.90%)
    At close: Jun 24, 2025, 3:59 PM
    40.61
    -1.84%
    After-hours: Jun 24, 2025, 04:40 PM EDT

    Tarsus Pharmaceuticals Statistics

    Share Statistics

    Tarsus Pharmaceuticals has 42.01M shares outstanding. The number of shares has increased by 10.13% in one year.

    Shares Outstanding

    n/a
    		 42.01M

    Shares Change (YoY)

    n/a
    		 10.13%

    Shares Change (QoQ)

    n/a
    		 8.84%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 36.27M

    Failed to Deliver (FTD) Shares

    n/a
    		 54

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 8.07M, so 19.22% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 8.07M

    Short % of Shares Out

    n/a
    		 19.22%

    Short % of Float

    n/a
    		 19.88%

    Short Ratio (days to cover)

    n/a
    		 16.68

    Valuation Ratios

    The PE ratio is -18.02 and the forward PE ratio is 33.25. Tarsus Pharmaceuticals's PEG ratio is 0.54.

    PE Ratio

    n/a
    		 -18.02

    Forward PE

    n/a
    		 33.25

    PS Ratio

    n/a
    		 11.38

    Forward PS

    n/a
    		 1.8

    PB Ratio

    n/a
    		 9.27

    P/FCF Ratio

    n/a
    		 -24.61

    PEG Ratio

    n/a
    		 0.54
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Tarsus Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.42, with a Debt / Equity ratio of 0.32.

    Current Ratio

    n/a
    		 4.42

    Quick Ratio

    n/a
    		 4.39

    Debt / Equity

    n/a
    		 0.32

    Debt / EBITDA

    n/a
    		 -0.68

    Debt / FCF

    n/a
    		 -0.86

    Interest Coverage

    n/a
    		 -15.36

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $566,417.96

    Profits Per Employee

    n/a
    		 $-357,752.32

    Employee Count

    n/a
    		 323

    Asset Turnover

    n/a
    		 0.49

    Inventory Turnover

    n/a
    		 4.9

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 53.25% in the last 52 weeks. The beta is 0.84, so Tarsus Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.84

    52-Week Price Change

    n/a
    		 53.25%

    50-Day Moving Average

    n/a
    		 45.05

    200-Day Moving Average

    n/a
    		 45.34

    Relative Strength Index (RSI)

    n/a
    		 40.09

    Average Volume (20 Days)

    n/a
    		 689,770

    Income Statement

    In the last 12 months, Tarsus Pharmaceuticals had revenue of 182.95M and earned -115.55M in profits. Earnings per share was -3.07.

    Revenue

    n/a
    		 182.95M

    Gross Profit

    n/a
    		 170.13M

    Operating Income

    n/a
    		 -120.57M

    Net Income

    n/a
    		 -115.55M

    EBITDA

    n/a
    		 -106.48M

    EBIT

    n/a
    		 -108.11M

    Earnings Per Share (EPS)

    n/a
    		 -3.07
    Full Income Statement

    Balance Sheet

    The company has 94.82M in cash and 72.45M in debt, giving a net cash position of 22.37M.

    Cash & Cash Equivalents

    n/a
    		 94.82M

    Total Debt

    n/a
    		 72.45M

    Net Cash

    n/a
    		 22.37M

    Retained Earnings

    n/a
    		 -360.21M

    Total Assets

    n/a
    		 500.75M

    Working Capital

    n/a
    		 394.46M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -83.03M and capital expenditures -1.57M, giving a free cash flow of -84.59M.

    Operating Cash Flow

    n/a
    		 -83.03M

    Capital Expenditures

    n/a
    		 -1.57M

    Free Cash Flow

    n/a
    		 -84.59M

    FCF Per Share

    n/a
    		 -2.25
    Full Cash Flow Statement

    Margins

    Gross margin is 92.99%, with operating and profit margins of -65.9% and -63.16%.

    Gross Margin

    n/a
    		 92.99%

    Operating Margin

    n/a
    		 -65.9%

    Pretax Margin

    n/a
    		 -63.16%

    Profit Margin

    n/a
    		 -63.16%

    EBITDA Margin

    n/a
    		 -58.2%

    EBIT Margin

    n/a
    		 -65.9%

    FCF Margin

    n/a
    		 -46.24%

    Dividends & Yields

    TARS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for TARS is $66, which is 62.9% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $66

    Price Target Difference

    n/a
    		 62.9%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 6.59

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist